ES2304913T1 - Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano. - Google Patents
Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano. Download PDFInfo
- Publication number
- ES2304913T1 ES2304913T1 ES07108593T ES07108593T ES2304913T1 ES 2304913 T1 ES2304913 T1 ES 2304913T1 ES 07108593 T ES07108593 T ES 07108593T ES 07108593 T ES07108593 T ES 07108593T ES 2304913 T1 ES2304913 T1 ES 2304913T1
- Authority
- ES
- Spain
- Prior art keywords
- xanthan gum
- ophthalmic composition
- composition according
- ophthalmic
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/723—Xanthans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Steroid Compounds (AREA)
Abstract
Goma de xantano para uso oftálmico como principio activo en un medicamento.
Claims (18)
1. Goma de xantano para uso oftálmico como
principio activo en un medicamento.
2. Uso de goma de xantano como principio activo
de un medicamento para la producción de un remedio para el
tratamiento de heridas epiteliales oftálmicas.
3. Uso de goma de xantano de acuerdo con la
reivindicación 2 en asociación con un medicamento seleccionado
entre antiinfecciosos, antiinflamatorios, anestésicos y
midriáticos.
4. Uso de goma de xantano de acuerdo con
cualquiera de las reivindicaciones 2 o 3, en el que dicho epitelio
es el epitelio corneal.
5. Uso de goma de xantano de acuerdo con
cualquiera de las reivindicaciones 2 a 4 para promover la
proliferación de células epiteliales.
6. Composición oftálmica
re-epitelizante sustancialmente en forma de gel
preformado que consiste en goma de xantano como principio activo y
aditivos farmacológicamente aceptables.
7. Composición oftálmica de acuerdo con la
reivindicación 6, en la que dicho principio activo comprende goma
de xantano en cantidades entre 0,7% y 5% del volumen total de dicho
gel preformado.
8. Composición oftálmica de acuerdo con la
reivindicación 6, en la que dicha goma de xantano está presente en
cantidades entre 0,8% y 3% del volumen total del gel preformado.
9. Composición oftálmica de acuerdo con la
reivindicación 6, en la que dicha goma de xantano está presente en
cantidades entre 0,9% y 1,5% del volumen total del gel
preformado.
10. Composición oftálmica de acuerdo con
cualquiera de las reivindicaciones 6 a 9, en la que dichos aditivos
incluyen agentes isotónicos, tampones, disolventes, antioxidantes,
agente de regulación del pH y similares.
11. Composición oftálmica de acuerdo con la
reivindicación 10, en la que dichos agentes isotónicos pueden ser
iónicos o no iónicos y su mezcla, los tampones pueden ser fosfato o
borato, acetato, citrato/acetato, TrisHCl, o basados en histidina o
arginina, los antioxidantes pueden ser citrato sódico, ascorbato o
sulfato, los agentes reguladores del pH pueden ser ácidos o bases
orgánicos o inorgánicos también junto con sus formas de sales, los
disolventes o vehículos pueden ser agua o una mezcla de
aceite/agua.
12. Composición oftálmica que consiste en:
\newpage
13. Composición oftálmica que consiste en:
\vskip1.000000\baselineskip
14. Composición oftálmica que consiste en:
\vskip1.000000\baselineskip
15. Composición oftálmica que consiste en:
\vskip1.000000\baselineskip
16. Método para la preparación de una
composición oftálmica re-epitelizante de acuerdo con
cualquiera de las reivindicaciones 6 a 15, que incluye las fases
de:
- disolver la cantidad adecuada de aditivos en
un volumen adecuado de agua;
- añadir, como se requieran, otros agentes
farmacológicos;
- esterilizar dicha disolución;
- dispersar en un volumen adecuado de agua una
cantidad predeterminada de goma de xantano sin agitación para
evitar la formación de conglomerados;
- esterilizar dicha dispersión;
- añadir a la dispersión de goma de xantano la
disolución de aditivos finalmente añadidos con agentes
farmacológicos y agitar evitando turbulencia;
- distribuir de forma aséptica el gel obtenido
en las fases precedentes en recipientes apropiados.
17. Método de acuerdo con la reivindicación 16,
en el que la fase de dispersión de goma de xantano tiene lugar
mediante homogeneización.
18. Composición oftálmica de acuerdo con una
cualquiera de las reivindicaciones 6-15, que tiene
una función mecánicamente protectora.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02425274A EP1358883B8 (en) | 2002-04-30 | 2002-04-30 | Re-epithelializing pharmaceutical compositions containing xanthan gum |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2304913T1 true ES2304913T1 (es) | 2008-11-01 |
ES2304913T3 ES2304913T3 (es) | 2012-03-01 |
Family
ID=28799773
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02425274T Expired - Lifetime ES2290264T3 (es) | 2002-04-30 | 2002-04-30 | Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano. |
ES07108593T Expired - Lifetime ES2304913T3 (es) | 2002-04-30 | 2002-04-30 | Composiciones farmacéuticas reepitelializantes que contienen goma de xantano. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02425274T Expired - Lifetime ES2290264T3 (es) | 2002-04-30 | 2002-04-30 | Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano. |
Country Status (15)
Country | Link |
---|---|
US (5) | US8912164B2 (es) |
EP (2) | EP1913948B1 (es) |
JP (2) | JP4837912B2 (es) |
CN (1) | CN100502884C (es) |
AT (2) | ATE367165T1 (es) |
AU (1) | AU2003230224B2 (es) |
BR (1) | BR0304655A (es) |
CA (2) | CA2749172C (es) |
DE (2) | DE07108593T1 (es) |
DK (1) | DK1358883T3 (es) |
ES (2) | ES2290264T3 (es) |
MX (1) | MXPA04010668A (es) |
PT (1) | PT1358883E (es) |
RU (1) | RU2297230C2 (es) |
WO (1) | WO2003092706A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE07108593T1 (de) * | 2002-04-30 | 2008-12-04 | Sifi S.P.A., Lavinaio-Aci | Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten |
BR0309890A (pt) | 2002-05-09 | 2005-05-10 | Medigenes | Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação |
JP4948176B2 (ja) * | 2004-09-28 | 2012-06-06 | 千寿製薬株式会社 | キサンタンガムおよびアミノ酸を含有する眼科用組成物 |
ITRM20050443A1 (it) * | 2005-08-12 | 2007-02-13 | Opocrin Spa | Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea. |
KR101381035B1 (ko) | 2006-03-23 | 2014-04-04 | 센주 세이야꾸 가부시키가이샤 | 잔탄검 및 글루코스를 포함하는 안약 조성물 |
EP2309980A1 (en) * | 2008-07-08 | 2011-04-20 | S.I.F.I. Societa' Industria Farmaceutica Italiana | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
JP5620168B2 (ja) * | 2010-06-30 | 2014-11-05 | Dsp五協フード&ケミカル株式会社 | キシログルカン−カチオン複合体及びそれを含有する安定化組成物 |
IT1404145B1 (it) * | 2010-12-27 | 2013-11-15 | Altergon Sa | Composizioni di acido ialuronico stabilizzate verso l'azione di degradazione del calore o degli enzimi |
EP2783689B1 (en) * | 2011-11-24 | 2019-09-25 | Toyo Sugar Refining Co., Ltd. | Keratoconjunctival protecting agent, or keratoconjunctival disorder inhibiting agent |
KR102588589B1 (ko) * | 2015-05-18 | 2023-10-16 | 히데미 카키하라 | 항균 물질 및 액상 항균제 및 액상 항균제의 제조 방법 |
RU2767913C2 (ru) | 2015-12-29 | 2022-03-22 | Интервет Интернэшнл Б.В. | Вакцина от кокцидиоза |
CN106236704A (zh) * | 2016-08-30 | 2016-12-21 | 上海昊海生物科技股份有限公司 | 一种兼具仿生和靶向功能的莫西沙星滴眼液及其制备方法 |
CN114245737A (zh) | 2019-06-11 | 2022-03-25 | 司斐股份有限公司 | 微乳剂组合物 |
IT202000002296A1 (it) * | 2020-02-06 | 2021-08-06 | Sifi Spa | Formulazioni topiche oftalmiche a base di xantano con ridotta posologia |
MX2021003369A (es) * | 2021-03-22 | 2022-09-23 | Laboratorios Grin S A De C V | Lágrima ocular triple. |
IT202200000821A1 (it) * | 2022-01-19 | 2023-07-19 | Sifi Spa | Formulazioni topiche oftalmiche a base di xantano con ridotta posologia |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
US4370324A (en) | 1980-09-17 | 1983-01-25 | Bernstein Joel E | Method and composition for treating and preventing irritation of the eyes |
US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
US4711780A (en) * | 1984-06-11 | 1987-12-08 | Fahim Mostafa S | Composition and process for promoting epithelial regeneration |
US4826872A (en) | 1986-12-03 | 1989-05-02 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for treatment of cataract |
JPH0723317B2 (ja) * | 1988-03-17 | 1995-03-15 | 生化学工業株式会社 | 角膜上皮層障害症治療剤 |
JPH0651638B2 (ja) * | 1989-02-13 | 1994-07-06 | 新技術事業団 | 角膜上皮創傷治療用点眼剤 |
US5271943A (en) * | 1989-10-27 | 1993-12-21 | Scott Health Care | Wound gel compositions containing sodium chloride and method of using them |
IT1243435B (it) * | 1990-10-05 | 1994-06-10 | Altergon Sa | Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti |
US5804213A (en) * | 1991-10-09 | 1998-09-08 | Lectec Corporation | Biologically active aqueous gel wound dressing |
US6277365B1 (en) * | 1997-09-18 | 2001-08-21 | Bausch & Lomb Incorporated | Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
DE20022450U1 (de) * | 1999-01-19 | 2002-01-17 | Mann Gerhard Chem Pharm Fab | Künstliche Tränenflüssigkeit in Gelform |
EP1318819A4 (en) * | 2000-08-23 | 2006-03-15 | Phairson Medical Inc | TREATMENTS OF TRAUMAS AND OTHER INDICATIONS |
US6919321B2 (en) * | 2000-12-20 | 2005-07-19 | Alcon, Inc. | Ophthalmic lubricating solution adapted for use in lasik surgery |
DE07108593T1 (de) * | 2002-04-30 | 2008-12-04 | Sifi S.P.A., Lavinaio-Aci | Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten |
-
2002
- 2002-04-30 DE DE07108593T patent/DE07108593T1/de active Pending
- 2002-04-30 DE DE60221227T patent/DE60221227T2/de not_active Expired - Lifetime
- 2002-04-30 EP EP07108593A patent/EP1913948B1/en not_active Expired - Lifetime
- 2002-04-30 AT AT02425274T patent/ATE367165T1/de active
- 2002-04-30 PT PT02425274T patent/PT1358883E/pt unknown
- 2002-04-30 DK DK02425274T patent/DK1358883T3/da active
- 2002-04-30 ES ES02425274T patent/ES2290264T3/es not_active Expired - Lifetime
- 2002-04-30 AT AT07108593T patent/ATE528009T1/de not_active IP Right Cessation
- 2002-04-30 ES ES07108593T patent/ES2304913T3/es not_active Expired - Lifetime
- 2002-04-30 EP EP02425274A patent/EP1358883B8/en not_active Expired - Lifetime
-
2003
- 2003-04-24 CA CA2749172A patent/CA2749172C/en not_active Expired - Lifetime
- 2003-04-24 RU RU2004131550/15A patent/RU2297230C2/ru active
- 2003-04-24 CA CA2484020A patent/CA2484020C/en not_active Expired - Lifetime
- 2003-04-24 JP JP2004500890A patent/JP4837912B2/ja not_active Expired - Lifetime
- 2003-04-24 BR BR0304655-9A patent/BR0304655A/pt not_active Application Discontinuation
- 2003-04-24 MX MXPA04010668A patent/MXPA04010668A/es active IP Right Grant
- 2003-04-24 WO PCT/IT2003/000257 patent/WO2003092706A1/en active Application Filing
- 2003-04-24 AU AU2003230224A patent/AU2003230224B2/en not_active Expired
- 2003-04-24 US US10/512,521 patent/US8912164B2/en active Active
- 2003-04-24 CN CNB038095068A patent/CN100502884C/zh not_active Expired - Lifetime
-
2008
- 2008-02-14 US US12/031,495 patent/US20080139522A1/en not_active Abandoned
- 2008-02-14 US US12/031,483 patent/US20080139502A1/en not_active Abandoned
- 2008-02-14 US US12/031,518 patent/US20080146530A1/en not_active Abandoned
-
2011
- 2011-01-14 JP JP2011005761A patent/JP5203472B2/ja not_active Expired - Lifetime
-
2016
- 2016-02-25 US US15/054,090 patent/US20160166601A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2304913T1 (es) | Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano. | |
US9555045B2 (en) | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions | |
ES2574757T3 (es) | Vehículos oftálmicos de liberación controlada | |
Almeida et al. | In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations | |
ES2094688B1 (es) | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. | |
ES2160803T3 (es) | Composicion farmaceutica de aplicacion topica, su procedimiento de produccion y su utilizacion. | |
EA200600750A1 (ru) | Трансдермальная фармацевтическая композиция | |
KR20040073503A (ko) | 안과용 및 이과용 약제학적 조성물의 점도 및 기타물리학적 성질을 개질시키기 위한 무기 나노입자의 용도 | |
KR20190049931A (ko) | 무자극성 안과용 포비돈-요오드 조성물 | |
GB2581656A (en) | Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders | |
JP2013543481A5 (es) | ||
CN102481268B (zh) | 眼科用组合物和白浊、沉淀的抑制方法 | |
JP2024061871A (ja) | 眼科組成物 | |
ES2321875T3 (es) | Preparacion oftalmica esteril,multifase, sin emulsionante aplicable en gotas. | |
PE20060484A1 (es) | Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina | |
Cucina et al. | Dual 0.02% chlorhexidine digluconate–0.1% disodium EDTA loaded thermosensitive ocular gel for Acanthamoeba keratitis treatment | |
ES2197781B1 (es) | Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno. | |
CN105283186A (zh) | 氯苯那敏或其盐的稳定化方法 | |
TW201350124A (zh) | 用於治療、控制、改善或逆轉乾眼症之病狀之醫藥組合物及方法 | |
JPH0296515A (ja) | 点眼液 | |
CN105025896A (zh) | 澄清的水性液体制剂 | |
ES2225573T3 (es) | Composiciones farmaceuticas que contienen tobramicina y goma xantana. | |
RU2533276C1 (ru) | Глазные капли на основе композиции фармацевтически приемлемой аддитивной соли кислоты и метилэтилпиридинола и таурина, содержащие композицию витаминов группы в | |
ES2377342T3 (es) | Remedio para enfermedades corneales | |
JP2019189607A (ja) | 眼科組成物 |